

## Bluestar Adisseo Company

### Communication Record of 2025 Q1 Onsite Result Presentation

#### I. Meeting Time

Adisseo held 2025 Q1 onsite result presentation at Shanghai Stock Exchange Beijing Base on 17<sup>th</sup> June 2025.

#### II. Participants or institutions

Regarding the investors through Teams online meeting, pls refer to the attached list for the institutions who participated in the meeting.

Important reminder: The list is prepared according to the attendance lists according to the registration information. The Company cannot guarantee the completeness and accuracy of the names of participating institutions. Investors are advised to pay attention.

#### III. Participants of the Company

Mr. Hao Zhigang, Chairman and General Manager (CEO)

Mr. Zang Hengchang, Independent Director

Mr. Frederic Jacquin, Deputy General Manager and Chief Operating Officer of the Company

Ms. Virginie Cayatte, CFO of the Company

Ms. Cai Yun, Secretary of the Board of Directors

#### IV. Meeting platform

Shanghai Stock Exchange Beijing Base Teams and SSE Roadshow Center  
(website: <https://roadshow.sseinfo.com/>)

#### V. Communication content

##### 1. Does the Company plan to explore business diversification via restructuring or mergers and acquisitions (M&A) in the future? What is the latest progress regarding Chongqing Feedkind?

- As an international company, mergers and acquisitions (M&A) have always been integral to Adisseo's business growth. In 2006, Adisseo joined Bluestar, filling the domestic gap in autonomous methionine production. In 2015, the Company successfully listed on the A-share market through asset restructuring. Subsequently, it completed three overseas acquisitions in 2018, 2020, and 2023, which strategically expanded its specialty products portfolio and strengthened the "dual pillar" strategy, particularly the specialty products segment.
- Looking ahead, the Company will continue to deepen its M&A strategic layout,

focusing on integration along the industrial chain while pursuing technologically synergistic, strategic investments to complement existing operations. To this end, a dedicated management team has been established to oversee target screening and execution of acquisitions. By systematically advancing capital operations and strategic implementation, Adisseo aims to build a sustainable value-creation ecosystem, opening new avenues for shareholder equity enhancement.

- FeedKind® is a nutritious, safe, and reliable single-cell protein product—and more importantly, it is a truly sustainable solution. It can be produced using less land and water, offering a promising alternative to traditional animal protein sources. FeedKind® holds significant potential for the sustainable development of aquaculture and broader animal farming.
- The Calysseo Chongqing plant is the world’s first demonstration-scale unit to apply disruptive fermentation technology for mass production. Given its technological advancement and pioneering nature, it requires more time for development and optimization. It is also strongly supported by the local government. The project is still in the ramp-up phase. Since Q2 2024, the plant has been operating stably and delivering qualified products. In Q1 2025, large-volume orders from the aquaculture market and a second round of sales to the pet food segment were successfully fulfilled, showing clear signs of commercial progress. In addition to replacing fishmeal, Adisseo is also emphasizing the nutritional value-added aspects of FeedKind®.
- Meanwhile, Adisseo will actively explore all feasible solutions to quickly and flexibly implement the established plans and to proactively mitigate any potential negative impacts arising from the longer-than-expected industrialization timeline of the FeedKind® protein innovation.

2. Given the uncertainty in global trade and increasing competition, what is the company’s outlook on methionine pricing?

- The current international trade environment is complex and volatile, yet methionine prices have demonstrated notable resilience. The sustained price increase in Q2 was primarily driven by supply-demand dynamics: On the demand side, as a bulk feed additive, over 50% of methionine applications focus on poultry feed. Benefiting from the rigid consumption of poultry products and the rising inclusion rates in feed formulations, the industry’s annual demand growth remains stable at 4-5%, serving as a core driver for underlying price strength. From the supply perspective, the release pace of new capacity remains uncertain and may exert short-term pressure on the market. However, medium- to long-term trends suggest that incremental capacity will gradually be absorbed, fostering a rebalanced supply-demand mechanism.
- Currently, we maintain a bullish outlook for methionine prices in the third quarter, while the fourth-quarter outlook hinges on capacity release dynamics.

As a leading global supplier with cost advantages and robust capacity expansion strategies, Adisseo leverages its international operational framework to continually solidify its competitive position in the industry.

3. How does the company differentiate itself in the methionine business in the face of domestic and international competition?
  - Adisseo reinforces its global leadership in animal nutrition by leveraging leading technologies in liquid methionine and integrated industrial chain advantages. Since joining Bluestar, the Company has successfully introduced advanced technologies and completed the construction and production of its domestic methionine facility (Nanjing plant). This established a dual-platform production layout spanning China and Europe, enabling flexible resource allocation and ensuring efficient, stable product supply for global customers. In recent years, while closely monitoring market dynamics and aligning with its strategic vision, Adisseo has advanced dual-track expansion in both liquid and solid methionine segments. Through targeted issuance projects, the Company has strengthened its product matrix to fully address diverse market demands.
  - Backed by a global operational network and deep client-centric service model, Adisseo demonstrates robust market penetration. While solidifying its localized production advantage in China, the Company leverages agile global supply chains and multinational service teams to deliver rapid response capabilities across core markets in Europe, America, Asia-Pacific, and the Middle East. Recognizing the unique requirements of liquid methionine, Adisseo innovates with an “product-equipment-service” integrated solution, providing precision dosing services and feed efficacy monitoring platforms to optimize formulation efficiency. This ecosystem-oriented approach, driven by customer needs, has significantly enhanced client stickiness, propelling a projected double-digit growth in methionine revenues in 2024.
4. The Company’s Q1 profit was partly generated by the rise in vitamin prices, and there is a fluctuation in vitamin pricing. What is the competitive landscape of the vitamin industry, and what are the Company’s strategy in this sector?
  - After safety incidents involving major competitors in the industry, the vitamin business demonstrated strong resilience in 2024. Currently, the future supply-demand dynamics of the vitamin sector have not fundamentally changed. As competitors’ capacities recover and domestic production capacities come online, the market is expected to gradually return to a normalized, oversupplied state.
  - The vitamin business of Adisseo holds distinct competitive advantages. It is not only a core component of our integrated animal nutrition solutions for customers but also a strategic bridge for building long-term client relationships. Customers consistently view Adisseo as a supplier of a full

range of vitamins. In the context of intensified competition in the vitamin market, firstly, the Company will further reduce costs and increase efficiency, maintain product cost advantages, and is expected to achieve significant results in the short to medium term. Secondly, Adisseo's vitamin business mainly sells to customers through procurement in China or Europe. The Company will fully utilize its international industrial layout and global procurement advantages to continuously provide customers with high-quality and fully traceable full range vitamin solutions. At the same time, we will actively enhance the added value by innovating some vitamin formulas.

- In summary, Adisseo will strengthen its vitamin business edge through synergistic operations, strategic utilization of European manufacturing platforms, comprehensive solution offerings, and enhanced collaboration with industry partners.

## 5. What is the status of research and development in synthetic biology?

- Synthetic Biology, initially proposed by B. Hobom in 1980 to describe gene recombination techniques, was internationally defined in 2003 as the study of artificial biological systems based on systems biology, genetic engineering, and engineering methods. Synthetic biology has since emerged as the third revolutionary wave in biotechnology, following the discovery of the "DNA double helix structure" and "genome technologies." The global research pace in synthetic biology has accelerated rapidly, and the Chinese government has placed high importance on its development. From national policies to scientific research and industrial transformation, especially in systematically building a synthetic biology framework and advancing continuous, intelligent innovation—significant investments have been made. Multiple local governments across China have also prioritized synthetic biology as a critical development domain, achieving breakthroughs in all dimensions.
- Progress and Development: Developed nations have formulated technology roadmaps and strategic plans for synthetic biology, offering strong policy support, engineering research platforms, and substantial funding for projects, yielding remarkable achievements. Chinese scientists have kept pace, pioneering technologies such as artificial starch synthesis from carbon dioxide, glucose and fatty acid synthesis via CO<sub>2</sub> reduction, contributing to carbon peaking and neutrality goals.
- Policy Support: The nation's guidance for synthetic biology has evolved through three phases: top-level design for the bioindustry, targeted development in specialized fields, and comprehensive promotion of downstream applications. Biomanufacturing, represented by synthetic biology, has been increasingly recognized as a strategic new productivity driver.
- Competitive Advantages: Robust policy backing has fostered a favorable environment for China's synthetic biology sector. Strong research capabilities underpin industrial applications, while large-scale industrial clusters

accelerate technology commercialization and upgrading. The vast market potential positions China's synthetic biology industry for broad prospects.

- **Industry Characteristics:** As a strategic emerging field, synthetic biology's R&D and commercialization involve long cycles. From foundational technological breakthroughs to industrial implementation, challenges include strain design, metabolic pathway optimization, pilot validation, scalable production, and regulatory approval, all of which require rigorous scientific verification and oversight.
- **Adisseo's Innovation Efforts:** Adisseo adheres to a culture of innovation, allocating no less than 3% of annual revenue to R&D, including investments in emerging fields like synthetic biology for methionine production as well as collaboration with Zhejiang University of Technology for bio-based methionine R&D. Secondly, the Company conducts research in the field of synthetic biology in its specialty product business, such as enzyme preparations. The Company is the world's largest producer of non-starch polysaccharides and will also increase its use of synthetic biotechnology to accelerate research and innovation. Finally, the Company actively engages in technology sharing with research institutions, such as collaborating with Beijing University of Chemical Technology and the Feed Industry Center of the Ministry of Agriculture and Rural Affairs, to strengthen Adisseo's technological layout in the fields of biotechnology and animal nutrition products, promote the Company's constant connection with the most advanced technology, and seize possible industrialization opportunities.

**6. As a SOE listed company, what initiatives will the Company implement to enhance market value management and shareholder returns?**

- As a state-owned enterprise, the Company has been continuously carrying out market value management work in accordance with the guidance of the SASAC and Sinochem, promoting high-quality development of the Company. To so do, the Company has been actively pursuing various market value management initiatives, including but not limited to increasing the dividend ratio and the frequency, implementing private equity placement, fully leveraging the advantages of state-owned enterprise attributes, expanding communication activities with diverse investors on a larger scale and across multiple levels.
  - Increasing the dividend ratio and the frequency of cash dividends to share the Company's development achievements. To enhance the Company's investment value and allow investors to fully benefit from its operational and developmental successes, Adisseo has increased the minimum dividend ratio from 30% to 40% and implemented interim and annual dividend policies in March and May 2025 respectively, ensuring its own sustainable and stable operation and long-term development.
  - This private placement aims to support the Company's strategic

development and effectively enhance its core competitiveness and growth potential. On the other hand, the Company hopes to optimize its equity structure through this placement, attract diversified strategic institutional investors, improve stock liquidity, and thereby enhance the Company's market performance.

- Investor Communication: We continuously monitor market dynamics and actively communicate with investors, establishing regular communication mechanisms with both domestic and foreign investors to convey the Company's confidence and determination in development.
- Fully leverage the advantages of being a SOE. First, as a listed company under Sinochem, we share the group's global strategic resources. For example, the powder methionine project with an annual production capacity of 150,000 tons leverages supply chain advantages through Sinochem Quanzhou Petrochemical within the industrial park in Quanzhou. Additionally, we benefit from the SOE background to secure low financing costs, providing financial assurance for strategic implementation.

7. Currently, the company's stock price is performing poorly. Conducting a private issuing at 80% of the current price would essentially allow the participants to pick up money off the ground. At this point in time and at this price level, does this private issuing constitute interests transfer? Who is protecting the interests of small and medium investors?

- Adisseo plans to issue A-shares to no more than 35 specific individuals this time, always upholding the principles of fairness, justice and transparency, strictly complying with relevant laws and regulations of the CSRC and the SSE. All major decisions are made with the long-term development of the company and the maximization of benefits for all shareholders as our fundamental objectives. This private issuing has been approved by the Board of Directors and shareholders' meeting, and absolutely no improper benefit transfer is involved in the process. The pricing of this private issuing strictly follows regulatory requirements, with the final offering price to be determined through market-based bookbuilding to ensure full compliance. In the future, after being reviewed and approved by the Shanghai Stock Exchange and completing the registration procedures with the China Securities Regulatory Commission, the Company will choose a suitable issuance window to ensure high-quality issuance and effectively safeguard the interests of all investors.
- Adisseo places importance on protecting the rights and interests of minority investors. We have established comprehensive corporate governance structures and information disclosure mechanisms to guarantee equal rights to information and participation for all shareholders. The Private Issuing Plan has been carefully designed after thorough consideration of market conditions, industry trends and the company's actual needs, aiming to optimize our capital



structure and support business development, ultimately creating greater value for all shareholders.

- We remain committed to protecting the legitimate rights and interests of all investors through standardized operations, transparent information disclosure and proactive investor communication. The company will continue to address minority investors' concerns with high priority, strictly fulfilling our information disclosure obligations in accordance with regulatory requirements to ensure transparency and fairness throughout the decision-making process.
8. The Company announced a private issuing plan in April 2024 to raise 3 billion yuan, which is projected to be completed no earlier than August or September 2025. Given the estimation of net profit exceeding 2.5 billion yuan for 2024 and 2025, is this private issuing still necessary under such profitability conditions?
- Adisseo places importance on shareholder interests and the optimization of its capital structure. This private issuing represents a prudent decision based on our long-term development strategy and funding requirements. To support the development strategy, the Company has increased investment efforts and capital expenditure in recent years, resulting in continuous growth of asset size and business scale. Considering industry trends and project development, further optimization of our capital structure is essential to enhance financial resilience, seize market opportunities, and strengthen long-term competitiveness.
  - The UoP projects through this private issuing are closely aligned with our core business, market demand, and corporate development strategy, serving as a key initiative to reinforce our main operations. The implementation of these projects will further elevate the company's market competitiveness, expand production and operational scale, optimize capacity allocation, improve profitability, and bolster sustainable development capabilities—ultimately delivering better investment returns and fostering healthy corporate growth.
  - In recent years, our "dual-pillar" strategy has focused on consolidating our global leadership in the methionine industry (particularly liquid methionine) while accelerating the development of specialty products. Among the funded projects:
  - The powder methionine project with an annual production capacity of 150,000 tons will significantly expand Adisseo's powder methionine capacity in China, optimizing product structure and global production layout to reduce costs, enhance efficiency, and ensure supply stability. The specialty feed additives project with an annual production capacity of 37,000 tons and SPain Ester Adisseo transfer project will drive product diversification, strengthen market competitiveness, and advance our strategic goal of establishing specialty products as the second business pillar.
  - After the completion of this issuing, the number of circulating shares of the company in the stock market will further increase, thereby enhancing the

liquidity of the listed company's stock, optimizing the shareholder structure, and introducing strategic investors. Leveraging our listed platform, we will conduct equity financing while utilizing our robust balance sheet for debt financing and other funding methods. This diversified approach ensures a stable and healthy capital structure, meeting the financial demands of rapid business expansion.

- Thanks to solid market demand, close pricing management across all business lines and ongoing implementation of operational excellence program, Adisseo is confident in the solid business performance in Q2 2025. Adisseo will continue to manage with agility and is fully engaged in delivering growth, improving margins and pursuing strategic investments for the future.

9. To boost market confidence, the state has introduced frequent policy measures, and many responsible companies have chosen to buy back and cancel their own shares. Yet, as a state-owned enterprise, your company has deliberately gone against the trend by opting for a private issuing at this time, severely undermining investor confidence and negatively impacting the healthy performance of the stock price. Where, then, lies your company's sense of responsibility and accountability?

- Adisseo has been closely monitoring national policy directions and capital market developments, consistently upholding an investor-responsible approach, strictly complying with regulatory requirements, and prudently advancing capital operations. This private issuing represents a crucial decision made in alignment with the company's long-term development strategy and industry competition needs, aiming to further consolidate our global leadership position in the animal nutrition additives sector.
- Upon completion of the private issuing, the Company's capital strength will be further enhanced. The total assets and net assets of the Company will increase, and working capital will be further enriched. Simultaneously, the Company's debt-to-equity ratio will correspondingly decrease, optimizing the Company's capital structure. This will enhance the Company's debt-paying ability and reduce financial risks. With the successful implementation of the fund-raising investment projects and effective utilization of the funds raised. The gradual release of project benefits will enhance the Company's operational scale and economic performance, thus bringing better investment returns to the Company and shareholders, while promoting the healthy development of the Company.
- This private issuing constitutes a key strategic initiative for the company, fully compliant with national policy orientations and corporate social responsibility requirements. We will continue to maintain investor confidence and foster long-term healthy stock price performance through transparent and standardized operations. To enhance the Company's investment value and allow investors to fully benefit from its operational and developmental successes, Adisseo has increased the minimum dividend ratio to 40% and



implemented interim and annual dividend policies in March and May 2025 respectively, ensuring its own sustainable and stable operation and long-term development.

- As a listed company under Sinochem Group, the Company leverages its central enterprise background to secure advantageous low-cost financing, providing financial assurance for strategic implementation. It also benefits from the Group's global strategic resources and synergies in M&A projects, continuously optimizing its industrial chain layout. The Company deepens internal industrial synergies within Sinochem Group through technology sharing and channel integration, enhancing operational efficiency. With a clear strategic framework, steady development trajectory, and consistent dividend policy, the Company faithfully fulfills its responsibilities and commitments as a central enterprise-listed company.

10. What is the Company's revenue situation for 2025 Q1? Are there any new business goals and plans for this year?

- In Q1 2025, revenue recorded a yoy double-digit growth of +23% to reach CNY4.3 billion and gross margin improved significantly by +14% yoy to CNY1.27 billion, driven by: strong revenue growth of performance products (+29%) thanks to both methionine and vitamin performance; sustained growth in Specialties (+7%) despite continuous challenging dairy market in China.

Methionine:

Adisseo achieved outstanding double-digit growth in methionine driven by:

- Continuous penetration and historical record of liquid methionine volume (+24%)
- Close price monitoring and agile pricing management
- High plant reliability with high yields in all plants, offsetting negative impact arising from high raw material price
- European plants are restarting smoothly after 1-month technical shut-down
- Technical maintenance shutdown of Nanjing plant has started

Vitamin:

The vitamins business demonstrates strong growth momentum in the quarter.

Specialty:

The specialty business continued its growth in yoy revenue (+7%) and in gross profit (+5%), thanks to:

- Monogastric species notably Selisseo (+21%), Feed Digestibility (+12%) and Palatability (+24%)
- As well as ruminant (+10%) driven by continuous improvement in North American market
- Thanks to solid market demand, close pricing management across all business lines and ongoing implementation of operational excellence program, Adisseo is confident in the solid business performance in Q2 2025. Adisseo will

continue to manage with agility and is fully engaged in delivering growth, improving margins and pursuing strategic investments for the future. Strong operational dynamics is being pursued with: Strong operational performance across plants thanks to the smooth execution of technical shutdowns; Continuous proactive supply management in methionine; Competitiveness enhancement program of Vitamin A and opportunity grasping in the market for all Vitamin products; Acceleration of specialties dynamics, leveraging the full range of services and product offerings; Well-positioned international set-up, including dual platforms, international teams and global marketing coverage, allowing for continuous optimization of supply to address tariff and supply chain fluctuation and to capture global market demand and local opportunities; Contribution from operational excellence and cost control measures.

**11. Does the Company have plans to expand into other businesses this year?**

- Since its establishment, the Company has been dedicated to the animal nutrition field and is committed to expanding and innovating within this sector, striving to enhance its market competitiveness. Adisseo is part of Sinochem's life sciences business sector and is the only subsidiary in the group that focuses on animal nutrition.
- In terms of business development, the Company continues to accelerate research and development (R&D) investments and innovation, while optimizing products and services. It will persistently increase R&D investment, actively promote innovation, and continuously enrich its product portfolio. Guided by market demands, the Company optimizes its service system, further strengthening its commitment to providing value-driven solutions for the entire industry. These solutions aim to holistically enhance animal nutrition, health, and sustainability, contributing to the high-quality development of the sector. Notably, the Company is advancing innovative research on applying synthetic biology technology to methionine production. Collaborations have been established with Beijing University of Chemical Technology and the Feed Industry Center of the Ministry of Agriculture and Rural Affairs for scientific research, as well as with Zhejiang University of Technology for bio-based methionine R&D. These efforts reinforce Adisseo's technological footprint in biotechnology and animal nutrition products, ensuring alignment with cutting-edge technologies and seizing potential opportunities for industrialization.
- Meanwhile, the Company has always been committed to exploring new models and paths for collaborative cooperation within the group, fully leveraging the synergistic effects brought about by internal resources to achieve complementary advantages. At the same time, the Company is also looking to the external market, actively seeking suitable targets for mergers and acquisitions, to accelerate its development in the field of specialty

products, laying a solid foundation for the Company's long-term development and value enhancement. The Company sees great growth potential in Specialty products and actively explores innovative products. Adisseo has carried out several small-scale mergers and acquisitions in recent years. The full integration of Nutriad, FRAmelco and Nor-Feed into Adisseo allows a high complement to existing product range, the addressed species, and the target markets and enables Adisseo to offer an integrated solution and to provide more value to customers.

Bluestar Adisseo Company  
19<sup>th</sup> June 2025

Attachment (in no particular order):

No.	Name of Institutions/Individuals
1	Zhongtai Securities
2	Dongxing Securities
3	China International Capital Corporation (CICC)
4	Zheshang Securities
5	Everbright Securities
6	HSBC Qianhai Securities
7	Guolian Minsheng Securities
8	HSBC Qianhai Securities
9	Guotai Haitong
10	CITICS
11	Huafu Securities Research Institute
12	Jinxiu Zhonghe (Beijing) Asset Management Co., Ltd
13	Guangzhou Haizhu Digital Economy Venture Capital Management Co., Ltd
14	Beijing Zhongcai Longma Capital Investment Management Co., Ltd
15	National Research Fund
16	Chengtong Fund
17	Yinfeng Venture Capital
18	Securities Daily